Statins - increasing or reducing the risk of Parkinson's disease?
March 2011
Article
volume 228, issue 1 pp 1-4.
| Related Files |
|---|
|
Redirect to publisher's version
(publisher's version.url.txt, 49 bytes) |
Repository contains one additional file which is not publicly available
Keywords
- human
- methodology
- signal transduction
- priority journal
- atorvastatin
- nonhuman
- note
- ischemic heart disease
- low density lipoprotein cholesterol
- risk reduction
- outcome assessment
- drug withdrawal
- hydroxymethylglutaryl coenzyme A reductase inhibitor
- placebo
- simvastatin
- rosuvastatin
- disease model
- drug efficacy
- tumor necrosis factor alpha
- drug megadose
- unindexed drug
- cytokine production
- ubidecarenone
- cholesterol blood level
- cyclic AMP responsive element binding protein
- cholesterol
- tremor
- nerve degeneration
- sample size
- medical research
- brain derived neurotrophic factor
- parkinsonism
- enzyme activation
- dopamine
- immunoglobulin enhancer binding protein
- Parkinson disease
- neuroprotection
- hydroxymethylglutaryl coenzyme A reductase
- dopamine 2 receptor
- multicenter study (topic)
- randomized controlled trial (topic)
- 1,2,3,6 tetrahydro 1 methyl 4 phenylpyridine
- alpha synuclein
- antioxidant activity
- cholesterol synthesis
- diffuse Lewy body disease
- dopamine 1 receptor
- dyskinesia
- enzyme synthesis
- fluindostatin
- lipid raft
- meta analysis (topic)
- mevalonic acid
- mitochondrial respiration
- mitogen activated protein kinase 1
- mitogen activated protein kinase 3
- mevinolin
- muscle rigidity
- peroxynitrite
- phase 2 clinical trial (topic)
- pitavastatin
- pravastatin
- protein aggregation
- protein kinase B
- protein p21
- tumor necrosis factor receptor 2
